3-[2-(tert-butyl-dimethyl-silanyloxy)-ethoxy]-benzaldehyde | 828242-83-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 3-[2-(tert-butyl-dimethyl-silanyloxy)-ethoxy]-benzaldehyde
• 英文别名: 3-(2-((tert-butyldimethylsilyl)oxy)ethoxy)benzaldehyde；3-[2-(tert-butyldimethylsilanyloxy)ethoxy]benzaldehyde；3-(2-{[tert-Butyl(dimethyl)silyl]oxy}ethoxy)benzaldehyde；3-[2-[tert-butyl(dimethyl)silyl]oxyethoxy]benzaldehyde
• CAS: 828242-83-7
• 化学式: C₁₅H₂₄O₃Si
• 分子量: 280.439
• InChiKey: WSWLGVMHMFJCLT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  19
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-[2-(tert-butyl-dimethyl-silanyloxy)-ethoxy]-benzaldehyde 在 咪唑 、 氢氟酸 、 溴 、 三苯基膦 作用下， 以 二氯甲烷 、 水 、 乙腈 为溶剂， 反应 1.0h， 生成 3-(2-溴乙氧基)苯甲醛
  参考文献：
  名称：

  Photoactivatable Fluorescein Derivatives Caged with a (3-Hydroxy-2-naphthalenyl)methyl Group

  摘要：

  The (3-hydroxy-2-naphthalenyl)methyl (NQMP) group represents an efficient photocage for fluorescein-based dyes. Thus, irradiation of the 6-NQMP ether of 2'-hydroxymethylfluorescein with low-intensity UVA light results in a 4-fold increase in emission intensity. Photoactivation of nonfluorescent NQMP-caged 3-allyloxyfluorescein produces a highly emissive fluorescein monoether. To facilitate conjugation of the caged dye to the substrate of interest via click chemistry, the allyloxy appendage was functionalized with an azide moiety.

  DOI：

  10.1021/jo501116g
• 作为产物：
  描述：

  间羟基苯甲醛 在 咪唑 、 caesium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 3-[2-(tert-butyl-dimethyl-silanyloxy)-ethoxy]-benzaldehyde
  参考文献：
  名称：

  JP2015531760A5

  摘要：

  公开号：

  JP2015531760A5

文献信息

• TREATMENT OF DISEASES BY EPIGENETIC REGULATION
  申请人：McLure Kevin G.

  公开号：US20130281399A1

  公开（公告）日：2013-10-24

  The present disclosure provides non-naturally occurring polyphenol compounds that inhibit the bromodomain and extra terminal domain (BET) proteins. The disclosed compositions and methods can be used for treatment and prevention of diseases or disorders that are susceptible to administration of a BET inhibitor.

  本公开提供了抑制溴结构域和额外末端结构域（BET）蛋白的非天然存在的多酚化合物。所公开的组合物和方法可用于治疗和预防对BET抑制剂易感的疾病或疾病。
• Anti-inflammatory agents
  申请人：Hansen Henrik C.

  公开号：US09238640B2

  公开（公告）日：2016-01-19

  Disclosed are novel compounds that are useful in regulating the expression of interleukin-6 (IL-6) and/or vascular cell adhesion molecule-1 (VCAM-1), and their use in the treatment and/or prevention of cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s). Also, disclosed are compositions comprising the novel compounds, as well as methods for their preparation.

  揭示了一种新型化合物，可用于调节白细胞介素-6（IL-6）和/或血管细胞粘附分子-1（VCAM-1）的表达，并且它们在治疗和/或预防心血管和炎症性疾病以及相关疾病状态中的用途，例如动脉粥样硬化、哮喘、关节炎、癌症、多发性硬化、牛皮癣和炎症性肠病以及自身免疫疾病。此外，还揭示了包含这些新型化合物的组合物，以及它们的制备方法。
• COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS
  申请人：Lantheus Medical Imaging, Inc.

  公开号：US20150196672A1

  公开（公告）日：2015-07-16

  The present invention provides compounds with imaging moieties for imaging a subject. The present invention also relates to systems, compositions, and methods for the synthesis and use of imaging agents, or precursors thereof. An imaging agent precursor may be converted to an imaging agent using the methods described herein. In some cases, a composition or plurality of imaging agents is enriched in 18 F. In some cases, an imaging agent may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs.

  本发明提供了具有成像基团的化合物，用于对受试者进行成像。本发明还涉及用于合成和使用成像试剂或其前体的系统、组合物和方法。成像试剂前体可以使用本文所述的方法转化为成像试剂。在某些情况下，组合物或多种成像试剂富集于 18 F。在某些情况下，成像试剂可用于成像受试者的感兴趣区域，包括但不限于心脏、心血管系统、心脏血管、大脑和其他器官。
• Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists
  申请人：Connolly Joseph Terrence

  公开号：US20050038016A1

  公开（公告）日：2005-02-17

  Compounds represented by Formula I: which are useful as are alpha-1A/B adrenoceptor antagonists, to methods of treating conditions associated with the activity of alpha-1A/B adrenoceptors, and to methods of making said compounds, wherein Ar, Z, R, R′, R 5 and R 10 are as defined herein.

  公式I所代表的化合物，可用作α-1A/B肾上腺素受体拮抗剂，用于治疗与α-1A/B肾上腺素受体活性相关的疾病的方法，以及制备所述化合物的方法，其中Ar、Z、R、R′、R5和R10如本文所定义。
• NOVEL ANTI-INFLAMMATORY AGENTS
  申请人：Hansen Henrik C.

  公开号：US20120040954A1

  公开（公告）日：2012-02-16

  Disclosed are novel compounds that are useful in regulating the expression of interleukin-6 (IL-6) and/or vascular cell adhesion molecule-1 (VCAM-1), and their use in the treatment and/or prevention of cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s). Also, disclosed are compositions comprising the novel compounds, as well as methods for their preparation.

  本发明涉及一种新型化合物，该化合物可用于调节白细胞介素-6（IL-6）和/或血管细胞黏附分子-1（VCAM-1）的表达，并且可用于治疗和/或预防心血管和炎症性疾病及相关疾病状态，例如动脉粥样硬化、哮喘、关节炎、癌症、多发性硬化症、牛皮癣和炎症性肠病以及自身免疫疾病。此外，本发明还涉及包含该新型化合物的组合物，以及其制备方法。